T

TScan Therapeutics
D

TCRX

2.17000
USD
-0.04
(-1.81%)
مغلق
حجم التداول
21,168
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
122,616,696
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: TScan Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.